Skip to main content
. 2011 Dec 13;14(10):1254–1264. doi: 10.1093/neuonc/nor202

Fig. 2.

Fig. 2.

ALCAM expression correlates with histological grade of glioma and prognosis for glioblastoma patients. (A) Immunohistochemical staining of anti-IDH1-R132H mAb in astrocytoma samples. (B) Percentages of ALCAM+ cells in IDH1-R132H mutation+ WHO grades II–IV glioma specimens. The horizontal bar shows the average percentages of ALCAM+ glioblastoma cells. (C) Plots for progression-free survival and overall survival of primary glioblastoma patients with high percentages (≧60%) and of those with low percentages (<60%) of ALCAM+ cells.